Micro-Cap Announces Test Results For Break-Through Product

By: AllPennyStocks.com News

July 21, 2009
Physicians and researchers call it difficile for a reason, for Clostridium difficile (C. difficile for short) is the spore considered most difficult to eliminate, among those deadly microorganisms to be found in most health care facilities. In the United States alone, more than two million patients get sick after being infected with what’s in the air at the facilities assigned to make them well, infections that kill about 100,000 patients a year.

Which is why a sigh of relief was announced in the third week of July when Newark, New Jersey-based BioNeutral Group Inc. (OTCBB:BONU) announced exciting news about a product that can fight C. difficile. BONU told the press its Ygiene™ Hospital Grade Antimicrobial passed the difficult Quantitative Disk Carrier test by totally eradicating all 5.4 million spores of Clostridium difficile from the air in 10 minutes at room temperature. This was a 100-per-cent kill rate in independent Environmental Protection Agency (EPA) testing. Few antimicrobials do nearly that well, putting BONU’s Ygiene in select company.

Headquartered at the New Jersey Institute of Technology/EDC in Newark and in existence since 2003, BioNeutral is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology to neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. Its literature claims the world’s “most efficient killers” - Ygiene, as we have seen, for health-threatening microorganisms, and Ogiene™ which aims its shaft at toxic gases and odors.

BONU’s entire sell line is that its products are environmentally-friendly at the same time as being effective. “The formulations”, says the company website, “are green and include natural and common ingredients which are found in baby products and in the foods we eat. The Company combines these widely-used compounds in unique ways to create enhanced results.

“BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. The products include BioNeutralizers and ChemoNeutralizers.”

As word gets out on the benefits of the company’s products are at killing the airborne toxins and germs that can kill us, consumers and investors alike will learn how significant this announcement can have on the Company’s bottom line. The day the news was announced on its success in killing C. difficile, the per share price was in around 30 cents, still in the basement of a 52-week range that bottomed out around 12 cents in April after peaking around $1.56 the month before. Investors are encouraged to take a closer look at this potential life saving Company.

Copyright © 2009 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.